Enlivex Therapeutics/$ENLV
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Enlivex Therapeutics
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.
Ticker
$ENLV
Sector
Primary listing
Employees
34
Headquarters
Ness Ziona, Israel
Website
ENLV Metrics
BasicAdvanced
$149m
0.02
$25.48
1.68
-
Price and volume
Market cap
$149m
Beta
1.68
52-week high
$2.10
52-week low
$0.62
Average daily volume
367k
Financial strength
Current ratio
193.236
Quick ratio
0.694
Long term debt to equity
0.02
Total debt to equity
0.033
Profitability
EBITDA (TTM)
-14.668
Effective tax rate (TTM)
23.65%
Management effectiveness
Return on assets (TTM)
-0.80%
Return on equity (TTM)
126.17%
Valuation
Price to earnings (TTM)
0.024
Price to book
0.08
Price to tangible book (TTM)
0.08
Price to free cash flow (TTM)
-2.694
Free cash flow yield (TTM)
-37.12%
Free cash flow per share (TTM)
-0.229
Growth
Earnings per share change (TTM)
-3,581.40%
3-year earnings per share growth (CAGR)
147.11%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs